|

CC312 Clinical Trials

4 actively recruiting trials

Pipeline

Early 1: 2Phase 1: 2

Top Sponsors

  • CytoCares Inc4

Indications

  • Lupus3
  • SLE - Systemic Lupus Erythematosus2
  • IIM- Idiopathic Inflammatory Myopathies1
  • SSc-Systemic Sclerosis1
  • Primary Immune Thrombocytopenia (ITP)1

Other4 trials

A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Early 1
Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
Phase 1
Safety Study of CC312 in Autoimmune Disease Patients
Early 1
Safety and Efficacy Study of CC312 for Moderate to Severe SLE
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.